On this page

Nystatin

Prescription ANDA TE AA Official labelling
Informational index, not medical advice. Content is reproduced from public FDA and NLM data. Always confirm against the manufacturer's current prescribing information. Report adverse events to FDA MedWatch.

Overview

Brand name
Nystatin
Generic name
Nystatin
Dosage form
Tablet, Film Coated
Route
Oral
Marketing category
ANDA · ANDA
Labeler
Teva Pharmaceuticals USA, Inc.
Product type
Human Prescription Drug
DEA schedule
Not scheduled
Active ingredients
1
NDC product codes
3
Packages
4
Data completeness
76% of corroborating sources present

Active ingredients

Source: NDC Directory
Active ingredients and strengths as listed in the NDC Directory.
Ingredient Strength RxCUI Monograph
Nystatin 500000 [USP'U]/1 261178 View

Forms, strengths and routes

Source: NDC Directory
Dosage form
Tablet, Film Coated
Route of administration
Oral
Presentations
7

Pharmacologic classes are listed in the class section below.

Pharmacologic class

Source: NDC Directory
Established pharmacologic classes (EPC), mechanisms of action (MoA), chemical structures (CS) and physiologic effects (PE).
Class Type Browse
Polyene Antifungal [EPC] EPC All 12 members
Polyenes [CS] CS All 13 members

Regulatory status

Source: Drugs@FDANDC Directory
Application number
062506
Application type
ANDA · Abbreviated New Drug Application
Approval date
January 16, 1984
Sponsor
TEVA
Products on application
1
Submissions recorded
33
Products approved under application 062506.
Product Trade name Form Strength Ingredient Status TE Flags
062506-001 NYSTATIN TABLET NYSTATIN Prescription AA RS

Therapeutic equivalence

Source: Orange Book
TE code
AA
Reference Listed Drug
No
Reference Standard
Yes

What this rating means: Therapeutically equivalent — no known or suspected bioequivalence problems (conventional dosage forms)

Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.

Approval history

Source: Drugs@FDA
Most recent submissions on application 062506.
Type No. Action Status Date Review
Supplement 39 Manufacturing (CMC) Approved August 30, 2001 —
Supplement 38 Manufacturing (CMC) Approved July 7, 2000 —
Supplement 37 Manufacturing (CMC) Approved December 21, 1999 —
Supplement 36 Manufacturing (CMC) Approved March 9, 1998 —
Supplement 35 Manufacturing (CMC) Approved August 19, 1997 —
Supplement 34 Manufacturing (CMC) Approved June 5, 1997 —
Supplement 33 Labeling Approved April 2, 1997 —
Supplement 30 Manufacturing (CMC) Approved January 7, 1997 —
Supplement 32 Manufacturing (CMC) Approved November 26, 1996 —
Supplement 31 Manufacturing (CMC) Approved October 4, 1996 —
Supplement 29 Manufacturing (CMC) Approved August 16, 1996 —
Supplement 28 Manufacturing (CMC) Approved January 25, 1996 —
Supplement 27 Manufacturing (CMC) Approved January 25, 1996 —
Supplement 26 Manufacturing (CMC) Approved January 25, 1996 —
Supplement 24 Manufacturing (CMC) Approved March 2, 1995 —
Supplement 25 Manufacturing (CMC) Approved February 10, 1995 —
Supplement 23 Labeling Approved February 9, 1994 —
Supplement 22 Manufacturing (CMC) Approved January 14, 1994 —
Supplement 21 Manufacturing (CMC) Approved January 14, 1994 —
Supplement 20 Manufacturing (CMC) Approved January 14, 1994 —
Supplement 19 Manufacturing (CMC) Approved January 14, 1994 —
Supplement 18 Manufacturing (CMC) Approved January 14, 1994 —
Supplement 17 Manufacturing (CMC) Approved January 14, 1994 —
Supplement 16 Manufacturing (CMC) Approved December 3, 1993 —
Supplement 15 Labeling Approved December 3, 1993 —
Supplement 14 Manufacturing (CMC) Approved December 3, 1993 —
Supplement 8 Manufacturing (CMC) Approved December 3, 1993 —
Supplement 13 Manufacturing (CMC) Approved August 31, 1993 —
Supplement 12 Manufacturing (CMC) Approved August 31, 1993 —
Supplement 11 Manufacturing (CMC) Approved April 1, 1993 —
Supplement 10 Manufacturing (CMC) Approved April 1, 1993 —
Supplement 9 Manufacturing (CMC) Approved April 1, 1993 —
Original application 1 Approved January 16, 1984 —

Prescribing information

Source: openFDA Drug Labeling

Reproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20251217). This is the manufacturer's labelling text, not a summary and not advice.

HUMAN PRESCRIPTION DRUG · 20251217 HUMAN PRESCRIPTION DRUG · 20250918 HUMAN PRESCRIPTION DRUG · 20221101

Indications and Usage

openFDA Drug Labeling

INDICATIONS AND USAGE Nystatin tablets are intended for the treatment of non-esophageal mucus membrane gastrointestinal candidiasis.

Dosage and Administration

openFDA Drug Labeling

DOSAGE AND ADMINISTRATION The usual therapeutic dosage is one to two tablets (500,000 to 1,000,000 units nystatin) three times daily. Treatment should generally be continued for at least 48 hours after clinical cure to prevent relapse.

Contraindications

openFDA Drug Labeling

CONTRAINDICATIONS Nystatin Tablets are contraindicated in patients with a history of hypersensitivity to any of their components.

Adverse Reactions

openFDA Drug Labeling

ADVERSE REACTIONS Nystatin is well tolerated even with prolonged therapy. Oral irritation and sensitization have been reported (see PRECAUTIONS, General ). Gastrointestinal Diarrhea (including one case of bloody diarrhea), nausea, vomiting, gastrointestinal upset/disturbances. Dermatologic Rash, including urticaria has been reported rarely. Stevens-Johnson syndrome has been reported very rarely. Other Tachycardia, bronchospasm, facial swelling, and nonspecific myalgia have also been rarely reported. To report SUSPECTED ADVERSE REACTIONS contact AvKARE at 1-855-361-3993; email drugsafety@avkare.com; or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Description

openFDA Drug Labeling

DESCRIPTION Nystatin, USP is an antimycotic polyene antibiotic obtained from Streptomyces noursei . Its structural formula: C 47 H 75 NO 17 M.W. 926.13 Nystatin tablets, USP are for oral administration and contain 500,000 units of nystatin, USP per tablet. Nystatin tablets, USP contain the inactive ingredients: corn starch, confectioner sugar, dibasic calcium phosphate, FD&C yellow #6, FD&C red #40, FD&C blue #2, hydroxypropyl cellulose, hypromellose, microcrystalline cellulose, magnesium stearate, polyethylene glycol, polysorbate 80, talc and titanium dioxide. Chemical Structure

OVERDOSAGE Oral doses of nystatin in excess of five million units daily have caused nausea and gastrointestinal upset. There have been no reports of serious toxic effects of superinfections (see CLINICAL PHARMACOLOGY, Pharmacokinetics ).

How Supplied / Storage and Handling

openFDA Drug Labeling

HOW SUPPLIED Nystatin tablets USP, 500,000 units are round, convex, brown, film-coated tablet debossed with 93 on one side and 983 on the reverse and are packaged in bottles of 100 tablets (NDC 0093-0983-01). Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]. Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required). Keep tightly closed. Keep this and all medications out of the reach of children. Manufactured In Canada By: Teva Canada Limited Toronto, Canada M1B 2K9 Manufactured For: Teva Pharmaceuticals Parsippany, NJ 07054 Rev. O 11/2022

Adverse event reports

Source: openFDA FAERS
27,387
FAERS reports mentioning this drug
as of 2026-09-25T03:42:24+00:00
A report count is not a risk measure. FAERS accepts voluntary and mandatory reports without establishing causation, and reporting is influenced by how widely a drug is used, how long it has been marketed, and media attention. FDA states that reports “do not prove that the drug caused the event”. Compare rates, not totals.

Attributed to this product's most-reported active ingredient: NYSTATIN. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.

Packaging and NDCs

Source: NDC Directory
Every National Drug Code package associated with this medication. The NDC is the identifier used for dispensing, billing and pharmacovigilance in the United States.
Package NDC Product NDC Labeler Description Marketing start
42291-651-90 42291-651 AvKARE 90 TABLET, FILM COATED in 1 BOTTLE (42291-651-90) January 20, 2014
62135-741-90 62135-741 Chartwell RX, LLC 90 TABLET, FILM COATED in 1 BOTTLE (62135-741-90) August 8, 2023
0093-0983-01 0093-0983 Teva Pharmaceuticals USA, Inc. 100 TABLET, FILM COATED in 1 BOTTLE (0093-0983-01) September 30, 1990
0093-0983-99 0093-0983 Teva Pharmaceuticals USA, Inc. 681818 TABLET, FILM COATED in 1 PAIL (0093-0983-99) June 23, 2023
42291-651 42291-651 AvKARE — January 20, 2014
62135-741 62135-741 Chartwell RX, LLC — October 31, 2011
0093-0983 0093-0983 Teva Pharmaceuticals USA, Inc. — September 30, 1990

Sources for this page

Every dataset that contributed a fact to this page.
Dataset Agency Used for
NDC Directory FDA Identity, ingredients, strengths, forms, routes, labelers, packages
Drugs@FDA FDA Application, sponsor, submissions, review documents, marketing status
Orange Book FDA Therapeutic equivalence codes, reference drug flags, patents, exclusivity
Drug Labeling FDA / NLM Prescribing information reproduced above
FAERS FDA Adverse event report counts

Generated September 25, 2026 · 12 sections on this page.